<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03317639</url>
  </required_header>
  <id_info>
    <org_study_id>MISSION CHINA</org_study_id>
    <nct_id>NCT03317639</nct_id>
  </id_info>
  <brief_title>Improving In-hospital Stroke Service Utilisation in China</brief_title>
  <official_title>Improving In-hospital Stroke Service Utilisation (MISSION) in China: A Cluster Randomised Trial of Interventions to Shorten Door to Needle Times</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shaoxing Second Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haining People' s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haiyan People' s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huzhou No.1 People' s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiashan No.1 People' s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo Medical Center Lihuili Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongxiang No.1 People' s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yiwu Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yongkang No.1 People' s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yuyao People' s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deqing People' s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dongyang People' s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jinhua People' s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lishui People' s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lin' an People' s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Longquan People' s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingtian People' s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaoxing Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wenzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangshan No.1 People' s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Central Hospital of Lishui City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A cluster randomised controlled trial will be conducted, using hospital as randomisation&#xD;
      unit. Hospitals in Zhejiang Province, China, will be randomised into two arms (1:1): an&#xD;
      intervention arm and a control arm. Hospitals in the intervention arm will receive a&#xD;
      multi-components intervention based on the Behaviour Change Wheel model, whereas hospitals in&#xD;
      the control arm will receive no intervention and maintain existing care. The randomisation&#xD;
      will be conducted after one-year baseline data collection. The following baseline data will&#xD;
      be used for randomisation match: hospital classification, beds in stroke centre, thrombolysis&#xD;
      patient number, and percentage of patients receiving thrombolysis within 60 minutes of stroke&#xD;
      onset. Hospitals with no stroke centre or with &lt;20 cases received thrombolysis per year will&#xD;
      be excluded from the study. The primary outcome will be difference between intervention arm&#xD;
      and control arm in the percentage of patients receiving thrombolysis within 60 minutes of&#xD;
      stroke onset on the follow-up stage (post-intervention).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the percentage of patients who Door-to-Needle Time≤60min</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Difference between intervention arm and control arm in the percentage of patients receiving thrombolysis within 60 minutes of stroke onset on the follow-up stage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Door-to-needle time</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>The time between hospital arrival and the initiation of IVT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset-to-needle time</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>The time between the symptom onset and the initiation of IVT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modified Rankin Scale score at discharge</measure>
    <time_frame>Up to 3 month</time_frame>
    <description>modified Rankin Scale score at discharge, on which scores range from 0 (no neurologic deficit) to 6 (death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracranial hemorrhage</measure>
    <time_frame>At 24 hours</time_frame>
    <description>Intracranial hemorrhage at 24 hours associated with an increase of ≥4 points of NIHSS score from baseline, according to European Cooperative Acute Stroke Study (ECASS) II trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Favorable neurological outcomes</measure>
    <time_frame>At 90 days</time_frame>
    <description>Score of 0 to 1 on the modified Rankin Scale, on which scores range from 0 (no neurologic deficit) to 6 (death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Up to 3 month</time_frame>
    <description>Death at discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1634</enrollment>
  <condition>Thrombolytic Therapy</condition>
  <condition>Acute Stroke</condition>
  <condition>Door to Treatment Time</condition>
  <condition>Quality Improvement</condition>
  <arm_group>
    <arm_group_label>an intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hospitals in the intervention arm will receive a multi-components intervention based on the Behaviour Change Wheel model</description>
  </arm_group>
  <arm_group>
    <arm_group_label>a control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>hospitals in the control arm will receive no intervention and maintain existing care</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behaviour Change Wheel model guided intervention</intervention_name>
    <description>Interventions are developed on a psychological model, the Behaviour Change Wheel (BCW) .The fundamental of BCW consists of three essential elements: capability, motivation, and opportunity. Improving individual's capability, providing motivation, and increasing opportunities are goals of behaviour change intervention. To achieve the goals, 9 intervention components have been proposed in the BCW framework, and 6 components will be used in current study.</description>
    <arm_group_label>an intervention arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AIS patients receiving IVT within 4.5 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are not willing to attend this trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The second affiliated hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 15, 2017</study_first_submitted>
  <study_first_submitted_qc>October 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>August 15, 2021</last_update_submitted>
  <last_update_submitted_qc>August 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

